Pfizer Q1 revenues $25.7B (+82%), EPS $1.62 adj.; reaffirms FY revenue $98-102B, adj. EPS $6.25-$6.45

PFIZER INC

2022-Q1 EPS reported $1.37 revenue$25,661,000,000

Revenues $25.7B up 82% operationally; ex-COVID products +2% operational growth.
Reported diluted EPS $1.37; Adjusted diluted EPS $1.62 (includes $0.05 negative from acquired IPR&D accounting change).
Full-year revenue guidance reaffirmed $98-$102B; adjusted EPS guidance revised to $6.25-$6.45 from $6.35-$6.55.
Comirnaty revenue guidance ~$32B; Paxlovid ~$22B; Chantix shipments remain paused globally due to impurity issue.
Pfizer repurchased 39.1M shares for $2B in March at avg $51.10; remaining authorization $3.3B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.